Skip to search formSkip to main contentSkip to account menu

mapatumumab

Known as: Anti-TRAIL R1-mAb, TRM-1 mAb 
A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

HGS-ETR1

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in a variety of tumor cells by engaging the… 
2012
2012
Hyperthermia‐enhanced TRAIL‐ and mapatumumab‐induced apoptotic death is mediated through mitochondria in human colon cancer cells
Colorectal cancer is the third leading cause of cancer‐related mortality in the world; death usually results from uncontrolled… 
2011
2011
Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis.
261 Background: Mapatumumab is a fully human agonist monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing… 
2011
2011
Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.
3008 Background: IAPs are key regulators of cancer cell survival, which makes them appealing targets for cancer therapy. HGS1029… 
2010
2010
A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.
LBA7501 Background: Mapatumumab, a fully human agonist monoclonal antibody, targets and activates the death receptor TRAIL-R1. We… 
Review
2009
Review
2009
Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1.
In spite of the advances in survival with chemotherapy and radiotherapy, many cancer patients continue to experience failure with… 
2008
2008
A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin
3540 Background: Mapatumumab (TRM-1, HGS-ETR1) is a fully human agonistic monoclonal antibody that binds and activates the tumor… 
Highly Cited
2007
Highly Cited
2007
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL‐R1 whereas cross‐linked agonistic TRAIL‐R2 antibodies facilitate signalling via TRAIL‐R2
Tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL), a member of the TNF family, which is being developed as… 
2007
2007
Bortezomib Sensitizes Non–Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2
Non–Hodgkin's lymphoma (NHL) is an increasingly common disease that, despite advances in antibody-targeted therapy, still… 
Review
2005
Review
2005
Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.
Human Genome Sciences and GlaxoSmithKline, under license from Cambridge Antibody Technology, are developing mapatumumab, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)